

Journal Information

Journal Title	JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
Publisher	BECARIS PUBLISHING
ISSN	2042-6305
E-ISSN	2042-6313
Database	Clarivate
Domain	Health Sciences, Life Sciences, Physical Sciences, Social Sciences

Classification History

Year	A+	A	B	C
2026		✓	✓	
2025		✓	✓	
2024		✓	✓	
2023		✓	✓	
2021/2022		✓	✓	
2020		✓	✓	
2019		✓	✓	
2018		✓		

Classification: The table above shows all journal classifications recorded for each classification year in the Green Journals database. A journal may have more than one classification in the same year.

Recent Articles

The impact of sequential analysis on drug decision-making in Canada 2026-10-27 Authors: Catherine Beauchemin, Jean Lachaine, Jean-Eric Tarride et al. DOI: 10.57264/cer-2026-0171
Cost-effectiveness analysis of nanosecond pulsed field ablation against hemithyroidectomy and total thyroidectomy for benign thyroid nodules 2026-10-26 Authors: Melissa Gomez Montero, Ralph P. Tufano, Victoria Zaitceva et al. DOI: 10.57264/cer-2026-0150
Real-world utilization of pembrolizumab dosing schedules in Belgium: a multi-center retrospective study using a common data model and natural language processing 2026-10-21 Authors: Annelies Verbiest, Hans Prenen, Annelies Janssens et al. DOI: 10.57264/cer-2026-0011
Comparative cost analysis of Eluvia[™] versus Zilver[®] PTX[®] in treating femoropopliteal peripheral artery disease utilizing real-world data 2026-10-21 Authors: Elizabeth A Genovese, Abimbola O Williams, Ryoko Sato et al. DOI: 10.57264/cer-2026-0126

<p>Letter to the Editor: Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema</p> <p>2026-10-19</p> <p>Authors: Irmgard Andresen, Natalie Khutoryansky, Sarah L Feeny et al.</p> <p>DOI: 10.57264/cer-2026-0018</p>	
<p>Corrigendum</p>	<p>2026-10-19</p> <p>DOI: 10.57264/cer-2026-0215</p>
<p>Response to Letter to the Editor regarding “Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema”</p> <p>2026-10-19</p> <p>Authors: Yinglei Li, Simona Gavata-Steiger, Chiara Nenci et al.</p> <p>DOI: 10.57264/cer-2026-0183</p>	
<p>Methodological considerations for indirect treatment comparisons of HIV incidence for long-acting injectable pre-exposure prophylaxis</p> <p>2026-10-15</p> <p>Authors: Tristan Curteis, Aidan N Franklin, Rebecca K Judge et al.</p> <p>DOI: 10.57264/cer-2026-0103</p>	
<p>Real-world cost-effectiveness of sequential therapy of in-class transition to ixazomib versus daratumumab for transplant-ineligible newly diagnosed multiple myeloma in China</p> <p>2026-10-13</p> <p>Authors: Genyong Zuo, Aijun Liu, Zunmin Zhu et al.</p> <p>DOI: 10.57264/cer-2026-0146</p>	
<p>Matching-adjusted indirect treatment comparisons in chronic inflammatory demyelinating polyneuropathy: interpreting current evidence and enhancing future studies</p> <p>2026-10-9</p> <p>Authors: Batyrkhan Kuvatov, Barkha P Patel, Muhaimen Siddiqui et al.</p> <p>DOI: 10.57264/cer-2026-0077</p>	